Breaking News Instant updates and real-time market news.

KBH

KB Home

$25.29

-0.24 (-0.94%)

, AIR

AAR Corp.

$46.03

1.04 (2.31%)

19:28
09/25/18
09/25
19:28
09/25/18
19:28

Fly Intel: After Hours Movers

UP AFTER EARNINGS: KB Home (KBH) up 6.0%... AAR Corp (AIR) up 4.2%. ALSO HIGHER: Verastem (VSTM) up 9.4% after signing COPIKTRA license agreement for development in China... Cancer Genetics (CGIX) up 5.8% after entering supply pact with Agilent... Vanda Pharma (VNDA) up 4.4% after entering S&P SmallCap 600 index... Nielsen Holdings (NLSN) up 3.5% on reports of interest from private equity groups... Community Health (CYH) up 3.2% after reaching settlement pact with DoJ over HMA probe... Aurinia Pharma (AUPH) up 2.5% after completing Phase 3 enrollment for AURORA... Canada Goose (GOOS) up 0.9% after being initiated at Buy at DA Davidson... Abbvie (ABBV) up 0.8% after receiving approval in Canada for VENCLEXTAR/Rituximab leukemia treatment. DOWN AFTER EARNINGS: Nike (NKE) down 3.4%... Cintas (CTAS) down 3.3%... Lululemon (LULU) down 0.6% after being initiated at Neutral at DA Davidson ALSO LOWER: CyrusOne (CONE) down 3.4% after equity offering.

KBH

KB Home

$25.29

-0.24 (-0.94%)

AIR

AAR Corp.

$46.03

1.04 (2.31%)

VSTM

Verastem

$7.15

-1.74 (-19.57%)

CGIX

Cancer Genetics

$1.22

-0.01 (-0.81%)

VNDA

Vanda Pharmaceuticals

$20.70

0.3 (1.47%)

NLSN

Nielsen

$27.21

0.055 (0.20%)

CYH

Community Health

$3.41

-0.08 (-2.29%)

AUPH

Aurinia Pharmaceuticals

$5.89

0.02 (0.34%)

GOOS

Canada Goose

$58.00

-0.04 (-0.07%)

ABBV

AbbVie

$93.78

0.34 (0.36%)

NKE

Nike

$84.79

0.52 (0.62%)

CTAS

Cintas

$212.99

1.81 (0.86%)

LULU

Lululemon

$158.42

1.04 (0.66%)

CONE

CyrusOne

$64.65

-0.6 (-0.92%)

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 04

    Oct

  • 05

    Oct

  • 26

    Sep

KBH KB Home
$25.29

-0.24 (-0.94%)

07/10/18
07/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CarMax (KMX) upgraded two notches to Overweight from Underweight at Morgan Stanley with analyst Armintas Sinkevicius saying longer term, he is constructive on dealers, citing a belief that tech disruption could accelerate consolidation and set up a transition toward "megafleet managers." 2. Cummins (CMI) upgraded to Buy from Hold at Stifel with analyst Michael Baudendistel saying shares of truck equipment companies have been under pressure primarily on concerns that the cycle is at a peak. 3. Wynn Resorts (WYNN) upgraded to Buy from Hold at Stifel with analyst Steven Wieczynski saying he believes the pullback in the stock recently has created a compelling opportunity. 4. KB Home (KBH) upgraded to Positive from Neutral at Susquehanna with analyst Jack Micenko citing a "clear and visible path" to further gross margin expansion and re-acceleration in community count and order growth well into 2019 for the upgrade, adding that underlying housing trends are strong in many of the markets in which the company currently operates despite "cautious" macro sentiment. 5. Quest Diagnostics (DGX) upgraded to Outperform from In Line at Evercore ISI with analyst Ross Muken saying the company will likely be the beneficiary of improved volumes, stable pricing, heightened M&A, and fund flows amid the heightened volatility within the Rx supply chain. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/18
MKMP
09/14/18
NO CHANGE
Target $36
MKMP
Neutral
KB Home Q3 earnings may miss, says MKM Partners
MKM Partners analyst Megan McGrath is keeping her Neutral rating and $36 price target on KB Home ahead of its earnings on September 25th, saying she expects EPS of 75c - below consensus 77c - to reflect the weak macro housing data over the summer. The analyst also forecasts a 5.7% order growth for the quarter with some downside risk as well as a 9% decline in community count and mid-teen absorption pace growth, adding that she will also monitor the company's gross margins and look for any insight into FY19 expectations.
07/10/18
SUSQ
07/10/18
UPGRADE
Target $36
SUSQ
Positive
KB Home upgraded to Positive from Neutral at Susquehanna
As previously reported, Susquehanna analyst Jack Micenko upgraded KB Home to Positive from Neutral and raised his price target to $36 from $34. In a research note to investors, Micenko cited a "clear and visible path" to further gross margin expansion and re-acceleration in community count and order growth well into 2019 for the upgrade, adding that underlying housing trends are strong in many of the markets in which the company currently operates despite "cautious" macro sentiment.
07/10/18
SUSQ
07/10/18
UPGRADE
SUSQ
Positive
KB Home upgraded to Positive from Neutral at Susquehanna
AIR AAR Corp.
$46.03

1.04 (2.31%)

09/11/18
09/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CBS (CBS) downgraded to Neutral from Buy at UBS with analyst John Hodulik saying uncertainty around the management transition limits upside in the shares and could last for an extended period. 2. Tesla (TSLA) downgraded to Neutral from Buy at Nomura Instinet with analyst Romit Shah expressing concern that the "erratic behavior" of CEO Elon Musk will taint the Tesla brand. 3. Johnson Controls (JCI) downgraded to Neutral from Buy at UBS with analyst Steven Winoker saying while the company's Buildings business is improving in 2018, the pace and magnitude of the progress is proving slower and lower than expectations. 4. Wingstop (WING) downgraded to Neutral from Buy at Goldman Sachs with analyst Karen Holthouse saying she continues to view the company's comps and unit growth fundamentals favorably but she recommends taking profits at current share levels. 5. AAR Corp. (AIR) downgraded to Hold from Buy at SunTrust with analyst Michael Ciarmoli saying he is maintaining a bullish view on the aero aftermarket with an opportunity for AAR Corp to exploit its position while also reaping benefits from its INL Global Aviation Support Services contract, but he also believes that the company's near-term growth will come under pressure from its maintenance, repair, and overhaul, or MRO, segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/18
ADAM
07/11/18
NO CHANGE
Target $52
ADAM
Buy
AAR Corp. price target raised to $52 from $48 at Canaccord
Canaccord analyst Ken Herbert maintained a Buy rating on AAR Corp and raised his price target to $52 from $48, telling investors in a research note that the company's Q4 adjusted EPS of 52c was slightly ahead of his 50c estimate, but consistent with prior guidance, with revenues growing 5% from the same quarter last year. Herbert says management indicated that the INL/A contract ramp up is on track, and he continues to see a significant step-up in FY19 EPS and free cash flow, which should be positive for the stock.
09/11/18
RHCO
09/11/18
DOWNGRADE
RHCO
Hold
AAR Corp. downgraded to Hold from Buy at SunTrust
09/11/18
RHCO
09/11/18
DOWNGRADE
Target $47
RHCO
Hold
AAR Corp. downgraded to Hold from Buy at SunTrust
As reported earlier, SunTrust analyst Michael Ciarmoli downgraded AAR Corp to Hold from Buy and lowered his price target to $47 from $50. The analyst notes that he is maintaining a bullish view on the aero aftermarket with an opportunity for AAR Corp to exploit its position while also reaping benefits from its INL Global Aviation Support Services contract, but he also believes that the company's near-term growth will come under pressure from its maintenance, repair, and overhaul, or MRO, segment. He cites tight labor condition in the unit as well as the delays associated with the company's new 737MAX/ A320NEO production, which combine to create a weaker than normal Q1 environment for AAR Corp.
VSTM Verastem
$7.15

-1.74 (-19.57%)

07/09/18
OPCO
07/09/18
NO CHANGE
Target $16
OPCO
Outperform
Verastem price target raised to $16 from $11 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Verastem to $16 from $11 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
07/13/18
BTIG
07/13/18
INITIATION
Target $17
BTIG
Buy
Verastem initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Verastem with a Buy rating and a price target of $17. The analyst cites the potential of the company's pipeline - namely the "late-stage, first-in-class molecule Duvelisib that selectively targets the delta and gamma phosphoinositide 3-kinase isoforms, central signaling pathways in cancer cell proliferation and survival". Hazlett adds that its " successful Phase 3 DUO trial in relapsed/refractory chronic lymphocytic leukemia, combined with solid data from the Phase 2 DYNAMO study in refractory follicular lymphoma, have led to Duvelisib receiving a Priority Review from FDA" with an upcoming Oct 5th PDUFA, as well as a licensing deal. The analyst models potential U.S. peak revenue over $500M and international revenue over $350M in Duvelisib's initial indications.
09/25/18
HCWC
09/25/18
NO CHANGE
Target $15
HCWC
Buy
Verastem price target raised to $15 from $10 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Verastem to $15 after the FDA approved the company's lead product, Copiktra , for the treatment of third-line chronic lympocytic leukemia, small lympocytic leukemia, and follicular lymphoma. Not unexpectedly, the FDA has included a boxed warning highlighting the increased risk of serious infections, diarrhea, and colitis with Copiktra, the analyst adds. He expects Copiktra to generate revenues of $178M for these three indications by 2025 and keeps a Buy rating on Verastem.
08/09/18
RAJA
08/09/18
NO CHANGE
RAJA
Verastem price target raised to $12 from $7 at Raymond James
CGIX Cancer Genetics
$1.22

-0.01 (-0.81%)

04/03/18
MAXM
04/03/18
DOWNGRADE
MAXM
Hold
Cancer Genetics downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Cancer Genetics to Hold from Buy citing the company's "disappointing" Q4 revenues and what he views as a lack of strategic direction at the company. The company's surprising increase in bad debt expense leaves him with concerns around the company's ability to collect account receivables, he added.
04/03/18
04/03/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Commercial Metals (CMC) downgraded to Neutral from Buy at Citi analyst Alexander Hacking saying multiple new rebar projects announced in recent months will offset the benefit of lower imports. 2. GameStop (GME) downgraded to Hold from Buy at Loop Capital with analyst Anthony Chukumba saying while the company's core video game business improved in fiscal 2017, its Technology Brands "dramatically underperformed," and collectibles sales missed expectations. 3. Manpower (MAN) downgraded to Underweight from Equal Weight at Barclays with analyst Manav Patnaik saying he believes good news is reflected in the current valuation and he expects Manpower to underperform its Temp Staffing peers. 4. Cancer Genetics (CGIX) downgraded to Hold from Buy at Maxim with analyst Jason McCarthy citing the company's "disappointing" fourth quarter revenues and what he views as a lack of strategic direction at the company. 5. Weatherford (WFT) downgraded to Neutral from Overweight at Piper Jaffray with analyst Bill Herbert saying the company's turnaround is taking longer than expected, and its balance sheet is "prodigiously heavy." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/29/18
HCWC
05/29/18
NO CHANGE
Target $3
HCWC
Buy
Cancer Genetics price target lowered to $3 from $6 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Cancer Genetics to $3 saying the company's growth has persistently lagged his projections. Nevertheless, Cancer Genetics is gradually growing sales, and its net loss should drop substantially starting late this year, Selvaraju tells investors in a research note. He reiterates a Buy rating on the shares.
12/07/17
12/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sogou (SOGO) initiated with an Overweight at JPMorgan. 2. Amag Pharmaceuticals (AMAG) initiated with a Neutral at B. Riley FBR. 3. Akebia (AKBA) initiated with a Buy at BTIG. 4. Synnex (SNX) initiated with a Buy at SunTrust. 5. Cancer Genetics (CGIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
VNDA Vanda Pharmaceuticals
$20.70

0.3 (1.47%)

05/23/18
05/23/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Quantenna Communications (QTNA) initiated with a Buy at Stifel. 2. Cesca Therapeutics (KOOL) initiated with a Buy at H.C. Wainwright. 3. W&T Offshore (WTI) initiated with a Neutral at Roth Capital. 4. Carrols Restaurant (TAST) initiated with a Buy at SunTrust. 5. Vanda initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/18
STFL
09/13/18
INITIATION
STFL
Buy
Vanda Pharmaceuticals initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated Vanda Pharmaceuticals with a Buy rating and $30 price target, citing the base business, Fanapt acceleration, and readouts from two meaningful clinical programs.
09/20/18
OPCO
09/20/18
INITIATION
OPCO
Outperform
Vanda Pharmaceuticals assumed with an Outperform at Oppenheimer
Oppenheimer analyst Esther Rajavelu assumed coverage of Vanda Pharmaceuticals with an Outperform rating and a raised $29 price target, up from $27. The analyst believes the Hetlioz uptake potential in the U.S. remains underappreciated, and sees mid-single to double-digit growth for Hetlioz.
08/22/18
CANT
08/22/18
INITIATION
Target $26
CANT
Neutral
Vanda Pharmaceuticals initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan initiated Vanda Pharmaceuticals with a Neutral and $26 price target.
NLSN Nielsen
$27.21

0.055 (0.20%)

08/29/18
PIPR
08/29/18
NO CHANGE
PIPR
Piper calls IHS Markit, S&P Global top picks in Information Services
Piper Jaffray analyst Peter Appert calls IHS Markit (IHS) and S&P Global (SPGI) his top picks in the Information Services sector. Dun & Bradstreet's (DNB) pending sale to a private equity group and Nielsen's (NLSN) strategic review refocuses investor attention on M&A activity in the sector, Appert tells investors in a research note. He says that while "rich" transaction values provide an "intriguing valuation backstop for the group," he continues to focus on operating fundamentals as the key driver of stock performance.
08/23/18
08/23/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ROSENBLATT BOOSTS AMD PRICE TARGET TO STREET HIGH: Rosenblatt analyst Hans Mosesmann raised his price target for AMD (AMD) shares to $30 from $27. Mosesmann's new price target represents the high among Wall Street sell-side analysts. Following the meetings, Mosesmann has renewed conviction in AMD's multi-year double digit growth profile. Further, he's impressed by the analysis investors are doing in the name after years of disregard. AMD is up 4.1% in late morning trading. CANTOR CUTS AETNA TO NEUTRAL: Cantor Fitzgerald analyst Steven Halper downgraded Aetna (AET) to Neutral from Overweight with a price target of $202. The stock now trades at just a 4.6% discount to the implied CVS Health (CVS) acquisition value of about $207 per share, Halper said. He believes the narrowed deal spread reflects an increased likelihood of regulatory approval. Halper cites limited potential upside for his downgrade of Aetna to Neutral. NIELSEN UPGRADED TO NEUTRAL AT GOLDMAN: Goldman Sachs analyst George Tong upgraded Nielsen Holdings (NLSN) to Neutral and raised his price target for the shares to $25 from $20. With activist Elliott Management pushing for a sale and increased deal activity in the Information Services sector, Tong sees increased likelihood of Nielsen being involved in a transaction. His upgrade to Neutral and price target increase come after the analyst incorporated a potential takeover into his model. Nielsen is up 3.3% in late morning trading. IMPERIAL SEES SUBSCRIBER UPSIDE FOR NETFLIX: Imperial Capital analyst David Miller believes Netflix's (NFLX) experiment with ending billing through Apple's (AAPL) app store in 33 countries outside the U.S. likely implies upside to its Q3 international subscriber guidance. The analyst said he has a tough time believing that Netflix would "experiment" with billing infrastructure mid-quarter if it did not believe that its international subscriber levels were trending ahead of guidance. As such, Miller raised his Q3 international subscriber estimate to 4.46M from 4.35M. He kept an Outperform rating on Netflix with a $494 price target. TARGET GETS UPGRADE AND DOWNGRADE: Target (TGT) was upgraded to Outperform from Market Perform at Telsey Advisory, and downgraded to Peer Perform from Outperform at Wolfe Research.
08/23/18
08/23/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Outperform from Market Perform at Telsey Advisory. 2. Deckers Brands (DECK) upgraded to Neutral from Negative at Susquehanna with analyst Sam Poser saying wholesale accounts are more positive than just a few months ago following checks with both large and small retailers. 3. Nielsen (NLSN) upgraded to Neutral from Sell at Goldman Sachs with analyst George Tong saying with activist Elliott Management pushing for a sale and increased deal activity in the Information Services sector, he sees increased likelihood of Nielsen being involved in a transaction. 4. Finisar (FNSR) upgraded to Overweight from Neutral at Piper Jaffray with analyst Troy Jensen saying China demand is returning via Huawei and ZTE (ZTCOY), Finisar is facing easy comps following five quarters of depressed demand and the upcoming 400G cycle should provide a tailwind in 2019. 5. Coca-Cola Amatil (CCLAY) upgraded to Equal Weight from Underweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/23/18
GSCO
08/23/18
UPGRADE
Target $25
GSCO
Neutral
Nielsen upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst George Tong upgraded Nielsen Holdings to Neutral and raised his price target for the shares to $25 from $20. With activist Elliott Management pushing for a sale and increased deal activity in the Information Services sector, Tong sees increased likelihood of Nielsen being involved in a transaction. His upgrade to Neutral and price target increase come after the analyst incorporated a potential takeover into his model.
CYH Community Health
$3.41

-0.08 (-2.29%)

08/14/18
LEHM
08/14/18
INITIATION
LEHM
Barclays starts Hospital sector with Neutral outlook, top pick HCA
Barclays analyst Steve Valiquette initiated coverage of the Hospital sector with a Neutral rating. Operators continue to face incremental pressures from alternative payment models that are shifting incentives towards lower-cost sites of care, Valiquette tells investors in a research note. He believes, however, that despite industry headwinds, operators levered to markets with high population growth and high relative market share will continue to outperform the industry. The analyst's only Overweight rated name in space is HCA Healthcare (HCA). The analyst initiated coverage of HCA with an Overweight rating and $150 price target. He sees HCA as well positioned in local markets. Valiquette also started Universal Health Services (UHS) and Tenet Healthcare (THC) with Equal Weight ratings. His lone Underweight rating is put on Community Health Systems (CYH). The company is still burdened with excessive debt and constrained free cash flow from its rural hospital footprint, Valiquette contends.
08/14/18
LEHM
08/14/18
INITIATION
Target $3
LEHM
Underweight
Community Health initiated with an Underweight at Barclays
Barclays analyst Steven Valiquette started Community Health Systems with an Underweight rating and $3 price target.
07/23/18
GSCO
07/23/18
NO CHANGE
GSCO
Deal activity could pick up after LifePoint takeout, says Goldman Sachs
Goldman Sachs analyst Stephen Tanal said that although the hospital industry appears to be grappling with secular challenges, hospitals are still generating meaningful and relatively predictable cash flows and mostly trading at lower multiples than other stocks in the broader healthcare space. Given an environment in which rates are low, credit is available and financial buyers have "dry powder," he believes deal activity could pick up following LifePoint's (LPNT) agreement to be bought by Apollo Global (APO) affiliates. Community Health (CYH), like LifePoint, should be "relevant for years to come" as its hospitals are often the sole provider of acute healthcare services in small towns or rural areas, according to Tanal. HCA Healthcare (HCA), in contrast, is positioned in fast-growing markets with high levels of commercial coverage, Tanal added.
03/23/18
MZHO
03/23/18
INITIATION
Target $4.5
MZHO
Neutral
Community Health resumed with a Neutral at Mizuho
Mizuho analyst Ann Hynes resumed coverage of Community Health Systems with a Neutral rating and $4.50 price target.
AUPH Aurinia Pharmaceuticals
$5.89

0.02 (0.34%)

08/13/18
HCWC
08/13/18
NO CHANGE
Target $15
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $15 after the company announced its pivotal Phase 3 study of voclosporin in lupus nephritis patients is running ahead of schedule. The analyst view the progress as a reflection of the high level of interest and motivation in the trial, by both patients and investigators. He keeps a Buy rating on Aurinia shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $9
RBCM
Outperform
Aurinia Pharmaceuticals initiated with an Outperform at RBC Capital
RBC Capital analyst Douglas Miehm initiated Aurinia Pharmaceuticals with an Outperform rating and a price target of $9. The analyst says the stock represents an "attractive opportunity with upside" based on the Phase 3 study of its lupus nephritis drug voclosporin, which "has potential to become the first FDA-approved treatment for the disease".
03/16/18
CANT
03/16/18
NO CHANGE
Target $16
CANT
Overweight
Aurinia price target raised to $16 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $16 citing a reduction of the company's estimated tax rate to 21% from 35% following its Q4 results. Aurinia remains on track to enroll its Phase 3 Aurora study in Q4 and to initiate studies to advance its pipeline indications for voclosporin in Q2, Piros tells investors in a research note. He reiterates an Overweight rating on the shares.
10/30/17
HCWC
10/30/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $12 after the company at its recent analyst day announced plans to expand voclosporin development to include focal segmental glomerulosclerosis and minimal change disease. The analyst maintains a Buy rating on the shares.
GOOS Canada Goose
$58.00

-0.04 (-0.07%)

09/25/18
DADA
09/25/18
INITIATION
Target $68
DADA
Buy
Canada Goose initiated with a Buy at DA Davidson
DA Davidson analyst John Morris initiated Canada Goose with a Buy rating and a price target of $68, saying that even though the investment sentiment on the stock is "bullish", its valuation still underestimates the company's "potential in several areas". The analyst cites the possibility of "expansion in the Far East, scale economies from in-house manufacturing growth, product pricing upside, and the potential for store acceleration and unit contribution". Morris expects Canada Goose to pull "multiple levers" to accelerate results and drive sales and earnings growth "beyond expectations".
08/01/18
BARD
08/01/18
DOWNGRADE
BARD
Neutral
Canada Goose downgraded to Neutral at Baird
As reported previously, Baird analyst Jonathan Komp downgraded Canada Goose to Neutral from Outperform. The analyst said fundamentals remain robust but the near-term valuation metrics are the highest in his coverage, suggesting possible vulnerabilities in the event near-term group sentiment moderates from current highs. Komp lowered his price target to C$80 from C$90 on Canada Goose shares.
08/01/18
BARD
08/01/18
DOWNGRADE
BARD
Neutral
Canada Goose downgraded to Neutral from Outperform at Baird
06/19/18
RBCM
06/19/18
NO CHANGE
Target $92
RBCM
Outperform
Canada Goose price target raised to $92 from $48 at RBC Capital
RBC Capital analyst Brian Tunick raised his price target on Canada Goose to $92 after its Q4 earnings, saying the higher than expected revenue and a move to profitability came at a historically unprofitable quarter. Tunick adds that the results suggest an inflection in the company's model and a shift to a "three-season" brand, with momentum driving further sales and earnings beats. The analyst keeps his Outperform rating on Canada Goose, further pointing to its "highly productive footage growth", even though he sees the company's valuation leaving little room for error.
ABBV AbbVie
$93.78

0.34 (0.36%)

09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
09/19/18
FBCO
09/19/18
NO CHANGE
Target $85
FBCO
Underperform
AbbVie's California lawsuit may have broader implications, says Credit Suisse
After the State of California has filed a lawsuit against AbbVie, accusing the company of paying kickbacks to doctors and using a network of nurses to illegally boost Humira prescriptions, Credit Suisse analyst Vamil Divan said he is "not surprised" by the stock's weakness given how leveraged it is to Humira sales and profit, and think there could be additional weakness as the story develops, especially if other states file similar lawsuits against the company. Additionally, he wonders how lawsuits like this may impact marketing practices across the industry. Divan maintains a cautious view on the stock with an Underperform rating and $85 price target, and says he continues to have concerns about the sustainability of Humira given the expected entry of multiple biosimilars in the EU next month expected biosimilar pressure in the U.S. starting in 2023.
09/10/18
BTIG
09/10/18
INITIATION
Target $32
BTIG
Buy
Voyager Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed Voyager Therapeutics (VYGR) with a Buy rating and a price target of $32, saying the company is an "attractive investment" based on its lead product for late-stage Parkinson's Disease patients and its "robust" adeno-associated viral technology platform. The analyst expects Voyager to be well served in its upcoming gene therapy market share competition and also cites the company's "productive FDA meetings"and the start of of a phase 2 trial. Shrader further notes that Voyager Therapeutics' latest Abbvie (ABBV) deal is a "vote of confidence" for its program.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $100
PIPR
Neutral
Piper more worried about AbbVie co-pay accumulator risk than California suit
While shares of AbbVie may move lower today on news of California's insurance regulator suing the company over promotion of Humira, a more fundamental potential drag on Humira remains the advent of co-pay accumulators, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst sees the California lawsuit as more headline risk than anything but thinks "it may nevertheless serve as a minor overhang on shares." He points out that new research this week by Drug Channels suggests that more than one-third of commercial lives are enrolled in plans that have implemented copay accumulators for 2018, higher than his prior best estimate of 17%. Raymond keeps a Neutral rating on AbbVie with a $100 price target.
NKE Nike
$84.79

0.52 (0.62%)

09/20/18
SUSQ
09/20/18
NO CHANGE
Target $100
SUSQ
Positive
Nike price target raised to $100 from $93 at Susquehanna
Susquehanna analyst Sam Poser raised his price target on Nike to $100 from $93 to reflect improving footwear sales trends and apparel sales momentum. The analyst said even Nike sportswear is showing momentum. Poser, who said the recent Kapernick campaign is driving an acceleration of brand awareness and sales, reiterated his Positive rating on Nike shares.
09/24/18
STFL
09/24/18
NO CHANGE
Target $96
STFL
Buy
Nike price target raised to $96 ahead of Q1 earnings report at Stifel
Stifel analyst Jim Duffy said his online checks into Q2 raise his confidence that in his above-consensus gross margin expectations ahead of Nike's Q1 earnings report, due tomorrow. Additionally, the firm's survey of 1,252 consumers, which showed positive spending intentions for both athletic apparel and athletic footwear, has increased his confidence in North American fundamentals, Duffy tells investors. Ahead of Tuesday's earnings report, Duffy raised his price target on Nike shares to $96 from $90 and he keeps a Buy rating on the stock.
09/21/18
LEHM
09/21/18
NO CHANGE
Target $100
LEHM
Overweight
Nike price target raised to $100 from $85 at Barclays
Barclays analyst Matthew McClintock raised his price target for Nike to $100 saying he now feels "comfortable enough to believe the current valuation multiple can at least roll forward in one year." The analyst remains a buyer of the Nike story heading into the fiscal Q1 results. Revenue momentum appears to be accelerating at the same time that the company's digital transformation could lead to a more efficient operating model, McClintock tells investors in a research note titled "Starting The New Year In Turbo." The analyst keeps an Overweight rating on Nike.
09/20/18
GUGG
09/20/18
NO CHANGE
Target $100
GUGG
Buy
Nike price target raised to $100 from $90 at Guggenheim
Guggenheim analyst Robert Drbul raised his price target on Nike to $100 and kept his Buy rating, saying he expects the company to sustain its momentum driven by its strong international segment that benefited from this year's World Cup excitement. The analyst also expects Nike's North America segment to grow about 3% thanks to its "onslaught of innovation" and direct-to-consumer growth, along with expected 60bps gross margin expansion and SG&A expense matching sales growth. Drbul adds that he is comfortable with his 65c estimate for Q1 EPS, which is slightly above the consensus view of 62c.
CTAS Cintas
$212.99

1.81 (0.86%)

01/25/18
BARD
01/25/18
NO CHANGE
Target $185
BARD
Outperform
Cintas long-term opportunity remains significant, says Baird
Baird analyst Andrew Wittmann believes Cintas' long-term opportunity remains significant with plenty of small items likely adding up to big share gains and strong financial returns over time. He believes the company's executive and operations-level management remain underappreciated and their execution will further separate them from the competition. Wittmann reiterated his Outperform rating and $185 price target on Cintas shares.
12/22/17
BARD
12/22/17
NO CHANGE
Target $185
BARD
Outperform
Cintas price target raised to $185 from $165 at Baird
Baird analyst Andrew Wittman raised his price target on Cintas to $185 from $165 following another solid beat. The analyst noted solid organic gains and gross margins, the on-track integration of G&K Services and solid long-term potential. He sees solid fundamentals and the company's competitive moat widening. Wittman reiterated his Outperform rating on Cintas shares.
08/10/18
FBCO
08/10/18
INITIATION
Target $205
FBCO
Neutral
Cintas initiated with a Neutral at Credit Suisse
Credit Suisse analyst Kevin McVeigh initiated shares of Cintas with a Neutral rating and $205 price target, telling investors in a research note that while Cintas is "the clear leader" in uniforms with impressive MSD-HSD growth, this is "more than reflected" in the stock price. Additionally, McVeigh says that given the current small business hiring environment that is moderating on tight supply and his late-cycle view, he does not see an attractive risk/reward at current levels.
03/27/18
GSCO
03/27/18
INITIATION
Target $210
GSCO
Conviction Buy
Cintas initiated with a Conviction Buy at Goldman Sachs
Goldman Sachs analyst George Tong started Cintas with a Conviction Buy rating and $210 price target. The analyst rolled out coverage on the Americas Business Services sector with an Attractive rating.
LULU Lululemon
$158.42

1.04 (0.66%)

09/17/18
09/17/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. LULULEMON UPGRADED TO OUTPERFORM: Wells Fargo analyst Ike Boruchow upgraded Lululemon (LULU) to Outperform from Market Perform, stating that while the brand's current strength is "evident to essentially everyone," his recent meetings with management lead him to believe that its "industry leading" momentum is likely sustainable through the second half of this year and well into 2019. While admitting to being "late to the party," Boruchow said he sees meaningful outperformance and upward revisions being ahead for the athletic apparel company. He raised his price target on Lululemon shares to $200 from $144. In late morning trading, Lululemon shares are higher by 2.3%. NOMURA UPGRADES BROADCOM TO BUY: Nomura Instinet analyst Romit Shah upgraded Broadcom (AVGO) to Buy from Neutral and raised his price target for the shares to $300 from $225. The analyst says the "so many positive takeaways from earnings" have forced him to take a more constructive stance on the shares. GOLDMAN SWAPS CONVICTION BUY ON MASTERCARD, VISA: Goldman Sachs analyst James Schneider added MasterCard (MA) to his firm's Conviction List while maintaining a Buy rating on the shares. The analyst also upped his price target for the stock to $260 from $230. Goldman Sachs analyst James Schneider removed Visa (V) from his firm's Conviction List but maintains a Buy rating on the shares with an unchanged price target of $160. The analyst, who continues to see upside to Street estimates, cites the recent share outperformance for the removal. MORGAN STANLEY INITIATES CONSUMER STAPLES: Morgan Stanley analyst Dara Mohsenian assumed Kraft Heinz (KHC) with an Underweight and $52 price target, as he believes it topline growth will likely trail food peers. In late morning trading, Kraft Heinz shares were down almost 2%. The analyst also assumed coverage of Mondelez (MDLZ), General Mills (GIS), and Kellogg (K) with Equal Weight ratings. KEYBANC SEES CANNABIS AS DRIVER FOR SHOPIFY: KeyBanc analyst Monika Garb said she is a buyer of Shopify (SHOP), as the company has "ample" growth opportunities ahead, and she sees potential upside to her above-consensus estimates. She expects that recreational sales of cannabis in Canada could be a GMV and revenue driver and further benefit Shopify's business momentum. Garb maintained an Overweight rating and $182 price target on the shares.
09/25/18
DADA
09/25/18
INITIATION
Target $155
DADA
Neutral
Lululemon initiated with a Neutral at DA Davidson
DA Davidson analyst John Morris initiated Lululemon with a Neutral rating and a price target of $155, saying the "quality of its long-term growth rate is not as robust as it has been" even though its forward earnings multiple is near historical highs. The analyst notes that the company's "future growth has higher risk variables associated with the complexity of international expansion across multiple continents and fashion cycle headwinds as the athleisure trend ebbs". Despite the risks, the analyst points to the company's "strong management team and powerful brand equity" in justifying his neutral stance.
09/17/18
09/17/18
UPGRADE
Target $200

Outperform
Wells Fargo upgrades Lululemon to Outperform, says momentum sustainable
As previously reported, Wells Fargo analyst Ike Boruchow upgraded Lululemon to Outperform from Market Perform, stating that while the brand's current strength is "evident to essentially everyone," his recent meetings with management lead him to believe that its "industry leading" momentum is likely sustainable through the second half of this year and well into 2019. While admitting to being "late to the party," Boruchow said he sees meaningful outperformance and upward revisions being ahead for the athletic apparel company. He raised his price target on Lululemon shares to $200 from $144.
09/17/18
09/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Teva (TEVA) upgraded to Neutral from Sell at BTIG with analyst Timothy Chiang citing the positive impact of the FDA approval for Ajovy in the prevention of episodic and chronic migraines. 2. American Express (AXP) upgraded to Overweight from Equal Weight at Stephens with analyst Vincent Caintic saying the company is successfully monetizing its card network by increasing merchant engagement to drive higher billed business volumes. 3. Lululemon (LULU) upgraded to Outperform from Market Perform at Wells Fargo with analyst Ike Boruchow saying while the brand's current strength is "evident to essentially everyone," his recent meetings with management lead him to believe that its "industry leading" momentum is likely sustainable through the second half of this year and well into 2019. 4. Broadcom (AVGO) upgraded to Buy from Neutral at Nomura Instinet with analyst Romit Shah saying "so many positive takeaways from earnings" has forced him to take a more constructive stance on the shares. 5. MasterCard (MA) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst James Schneider saying he continues to see upside to consensus estimates over the next 12 months driven by core consumer volume and exposure to Europe and other growth markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CONE CyrusOne
$64.65

-0.6 (-0.92%)

09/20/18
BREN
09/20/18
INITIATION
Target $64
BREN
Hold
CyrusOne initiated with a Hold at Berenberg
Berenberg analyst Nate Crossett started CyrusOne with a Hold rating and $64 price target.
08/14/18
MUFG
08/14/18
NO CHANGE
Target $68
MUFG
Overweight
CyrusOne to 'successfully' address new demand vectors, says MUFG
MUFG analyst Stephen Bersey kept his Overweight rating and $68 price target on CyrusOne, saying his recent meetings with the CEO Gary Wojtaszek added to his confidence in the company's ability to address new demand vectors in AI and autonomous cars. The analyst adds that he also has new insight into CyrusOne's demand drivers that should accelerate its total addressable market expansion over the next several years.
08/02/18
MUFG
08/02/18
NO CHANGE
Target $68
MUFG
Overweight
CyrusOne price target raised to $68 from $58 at MUFG
MUFG analyst Stephen Bersey raised his price target for CyrusOne (CONE) to $68 from $58 following a "strong" quarter. The analyst thinks CyrusOne performed well in the quarter, and calls attention to its record bookings with material contributions from the partnership with Chinese data center partner GDS (GDS) in the form of 10MW in leases signed from Chinese hyperscale tenants. Bersey reiterates an Overweight rating on CyrusOne shares.
08/07/18
RBCM
08/07/18
NO CHANGE
Target $73
RBCM
Sector Perform
CyrusOne price target raised to $73 from $59 at RBC Capital
RBC Capital analyst Jonathan Atkin raised his price target on CyrusOne to $73 and kept his Sector Perform rating after its Q2 results, saying that while it missed on the top-line, its leasing business outperformed expectations. The analyst states that his new price target is also driven by the roll forward impact of his discounted cash flow valuation model.

TODAY'S FREE FLY STORIES

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

FN

Fabrinet

$55.23

0.67 (1.23%)

17:25
02/15/19
02/15
17:25
02/15/19
17:25
Hot Stocks
Fabrinet CFO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

UBER

Uber

$0.00

(0.00%)

17:24
02/15/19
02/15
17:24
02/15/19
17:24
Periodicals
Uber sues NYC over move to cap number of ride-hailing drivers, Bloomberg says »

Uber is suing New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

17:19
02/15/19
02/15
17:19
02/15/19
17:19
Periodicals
House Democrats to probe POTUS emergency declaration, Bloomberg says »

The House Judiciary…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$51.71

0.25 (0.49%)

17:11
02/15/19
02/15
17:11
02/15/19
17:11
Hot Stocks
Oracle authorizes additional $12B stock buyback under existing program »

In a regulatory 8K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

SBLK

Star Bulk Carriers

$8.21

0.13 (1.61%)

17:03
02/15/19
02/15
17:03
02/15/19
17:03
Hot Stocks
Star Bulk Carriers acquires 95,605 of its common shares »

Star Bulk Carriers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.